Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in... see more

Bullboard (CSE:WBIO)

View:
Post by etceteraon Jul 06, 2020 7:51am

Updates on Annamycin and WP1066

VANCOUVER, British Columbia, July 06, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. On June 25, Moleculin announced its presentation at the American Association of Cancer Research (AACR) Annual ...more  
Post by etceteraon Jun 22, 2020 8:39am

WPD licensor confirms WP1122's anti-viral potential

Moleculin Biotech Inc., the company that sublicenses the WP1122 compound to WPD Pharmaceuticals Inc. for WPD's use in 29 countries mainly in Europe, announced on June 16, 2020, that a repeat of ...more  
Comment by etceteraon Jun 11, 2020 8:46am

RE:WPD Pharmaceuticals clarifies WP1122 disclosure

Well, the SARS-COV-2  seems to be a path to follow as there is another company that is working on it Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise's ...more  
Post by etceteraon Jun 11, 2020 7:12am

WPD Pharmaceuticals clarifies WP1122 disclosure

The future looks quite promising for  WPD1122 In an April 9, 2020, press release, WPD disclosed that independent research found 2-deoxy-D-glucose (2-DG) to reduce replication of SARS-CoV-2, the ...more  
Post by etceteraon May 28, 2020 8:22am

WPD Pharmaceuticals Licensor Granted Another Key Patent

VANCOUVER, British Columbia, May 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce ...more  
Comment by etceteraon May 05, 2020 4:16pm

RE:RE:IIROC Trading Halt - WBIO

It is " bizarre " that the SEC in the United States stop a canadian company operating in CANADA In the meantime, here is a comment from WBIO The Company has contacted the SEC regarding ...more  
Comment by suomynonaon May 05, 2020 10:21am

RE:RE:News Release Wording Over The Top?

Texas cancer-focused biotech Moleculin said its shares had been placed in a temporary trading halt following notification from the SEC. The small company, which has a market cap of about $65 million, ...more  
Comment by existaboon May 05, 2020 9:01am

RE:IIROC Trading Halt - WBIO

Well well, the SEC also halt trading... Now this is serious, any thought ???
Post by etceteraon May 04, 2020 2:15pm

IIROC Trading Halt - WBIO

News provided by Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions May 04, 2020, 14:02 ET   VANCOUVER, May 4, 2020 /CNW/  ...more  
Comment by existaboon May 04, 2020 1:46pm

RE:Leading Polish Medical Institutions for Berubicin Phase 2

So much pumping,press release day afterday ,  yet no volume to follow through...
Post by etceteraon Apr 30, 2020 8:13am

Leading Polish Medical Institutions for Berubicin Phase 2

WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial Trials to be funded by a US$6 million grant previously awarded to WPD ...more  
Post by etceteraon Apr 29, 2020 9:54am

No CARDIOTOXICITY

Mariusz Olejniczak, CEO of WPD commented, "As Annamycin continues to advance, and studies so far have demonstrated the absence of any cardiotoxicity, we believe the trial can and should move ...more  
Post by etceteraon Apr 29, 2020 9:50am

WPD receives approval for Annamycin dose escalation

2020-04-29 07:33 ET - News Release   Mr. Mariusz Olejniczak reports WPD PHARMACEUTICAL'S ANNAMYCIN DRUG APPROVED FOR ACCELERATED EUROPEAN CLINICAL TRIAL Through its licence partner ...more  
Post by hintonkidon Apr 23, 2020 1:34pm

Gilead's CORVID-19 drug candidate fails in first trial.

I was just watching BNN Bloomberg a short while ago.  Gilead's much touted CORVID-19 drug candidate has failed in it's first trial.  As a result of the news, which was allegidly ...more  
Post by ROUGETRADER719on Apr 13, 2020 1:36pm

Do be fooled or shook out there in the right place

With bigger pharma interested in the meds this is a buyout or a big runner sooner than later imo  theny ran it up then triggered stops , the high of today will be support in days and weeks to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities